CELC vs. CSTL, FLGT, CDNA, SERA, VRDN, ENZ, RNLX, XGN, DMTK, and CNTG
Should you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Castle Biosciences (CSTL), Fulgent Genetics (FLGT), CareDx (CDNA), Sera Prognostics (SERA), Viridian Therapeutics (VRDN), Enzo Biochem (ENZ), Renalytix (RNLX), Exagen (XGN), DermTech (DMTK), and Centogene (CNTG). These companies are all part of the "medical laboratories" industry.
Castle Biosciences (NASDAQ:CSTL) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.
92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 7.2% of Castle Biosciences shares are owned by insiders. Comparatively, 24.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Castle Biosciences has higher revenue and earnings than Celcuity. Castle Biosciences is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.
Celcuity received 243 more outperform votes than Castle Biosciences when rated by MarketBeat users. Likewise, 66.60% of users gave Celcuity an outperform vote while only 62.02% of users gave Castle Biosciences an outperform vote.
In the previous week, Castle Biosciences had 4 more articles in the media than Celcuity. MarketBeat recorded 6 mentions for Castle Biosciences and 2 mentions for Celcuity. Celcuity's average media sentiment score of -0.16 beat Castle Biosciences' score of -0.50 indicating that Castle Biosciences is being referred to more favorably in the media.
Celcuity has a net margin of 0.00% compared to Celcuity's net margin of -26.15%. Celcuity's return on equity of -14.92% beat Castle Biosciences' return on equity.
Castle Biosciences presently has a consensus price target of $31.00, indicating a potential upside of 38.08%. Celcuity has a consensus price target of $29.00, indicating a potential upside of 65.15%. Given Castle Biosciences' higher possible upside, analysts clearly believe Celcuity is more favorable than Castle Biosciences.
Castle Biosciences has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.
Summary
Castle Biosciences beats Celcuity on 9 of the 16 factors compared between the two stocks.
Get Celcuity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celcuity Competitors List
Related Companies and Tools
